Manchester Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Manchester Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-82	Closed	-$12K	–	1056
2022 Q2	$12K	Hold	82	–	–	﹤0.01%	468
2022 Q1	$10K	Sell	82 -81	-50%	-$10.1K	﹤0.01%	546
2021 Q4	$22K	Hold	163	–	–	﹤0.01%	477
2021 Q3	$23K	Buy	163 +151	+1,258%	+$18.9K	﹤0.01%	504
2021 Q2	$1K	Buy	+12	New	+$974	﹤0.01%	787
2019 Q2	–	Sell	-1,018	Closed	-$52K	–	688
2019 Q1	$52K	Buy	+1,018	New	+$44K	0.01%	403

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Manchester Capital Management's BHVN Position: Q3 2022 in Review

Manchester Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 82 shares — an estimated $12K sold.

Manchester Capital Management first reported a position in BHVN in Q1 2019 and held it in 6 quarters. The position peaked at $52K in Q1 2019. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Manchester Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Manchester Capital Management sold 82 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $12K.
Manchester Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 6 quarters.
Manchester Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $52K in Q1 2019.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Manchester Capital Management's 13F filing for Q3 2022, filed 8 Nov 2022.